Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects

Clinical Pharmacology and Therapeutics
P TanswellD C Rijken

Abstract

Pharmacokinetics and systemic effects of recombinant tissue-type plasminogen activator (rt-PA) were studied in 18 healthy male volunteers after 30-minute intravenous infusions of placebo, 0.25 mg/kg rt-PA, and 0.5 mg/kg rt-PA. Highly comparable pharmacokinetic parameters were obtained after analysis of rt-PA as both an antigen and an activity. Mean clearance (antigen) was 620 +/- 70 (SD) ml/min, volume of distribution at steady state was 8.1 +/- 0.8 L, initial volume of distribution was 4.4 +/- 0.6 L, and dominant half-life was 4.4 +/- 0.3 minutes. The pharmacokinetics of rt-PA were linear, showed low interindividual variation, and are compatible with rapid hepatic elimination of the protein. Systemic plasminogen activation was minimal as assessed by hemostatic assays of plasma samples treated with anti-rt-PA Immunoglobulin G (IgG) to inhibit in vitro fibrinogenolysis. Circulating fibrinogen levels, clotting times, and coagulation factors were unchanged; plasminogen and alpha 2-antiplasmin decreased maximally to 85% and 65% of baseline values, respectively. The data are consistent with the fibrin specificity of t-PA, which is derived from its role in physiologic fibrinolysis.

Citations

Sep 1, 2011·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Denis VivienEmmanuel Touzé
May 15, 2015·Clinical Neuropharmacology·Stefan BrodoehlCarsten M Klingner
Feb 5, 2019·Expert Opinion on Drug Safety·Katleen Wyatt ChesterGeorge M Dillon
Dec 5, 2012·International Journal of Stroke : Official Journal of the International Stroke Society·Curtis SmithArshad Majid
Jan 18, 2012·Expert Opinion on Drug Metabolism & Toxicology·Paul Acheampong, Gary A Ford
May 16, 2013·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Jason M MeunierGeorge J Shaw
Dec 6, 2001·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·M JørgensenK H Tønnesen
Jun 19, 2013·Scandinavian Journal of Clinical and Laboratory Investigation·Caroline U NilssonMartin Engström
Oct 27, 2018·Scientific Reports·Andris PiebalgsXiao Yun Xu
Dec 27, 2018·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Roberto PicettiIan Roberts
Dec 14, 2018·Pharmacology Research & Perspectives·Eriko SuzukiKeiji Hasumi
Jul 23, 2004·Expert Opinion on Therapeutic Targets·Nathalie LebeurrierCarine Ali
Jan 23, 2021·International Journal of Molecular Sciences·Keiji Hasumi, Eriko Suzuki
May 26, 2011·Journal of Cell Science·Benoit D RousselCarine Ali
May 11, 2021·Thrombosis Research·M J BakkumP R Tuinman
Sep 1, 1991·Progress in Cardiovascular Diseases·J HenkinH C Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.